Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer
Journal for ImmunoTherapy of Cancer · 2026
DOI: 10.1136/jitc-2026-016133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Carmen Fernández-Luna und 32 weiteren Autor:innen. Beteiligte Einrichtung: Tumor Microenvironment and Precision Oncology Research Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Community of Madrid, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, OX40 Ligand, Immune Checkpoint Inhibitors. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Science, Innovation, and Universities of Spain, Fundacion Cris, Asociación Española contra el Cáncer.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment. Understanding the tumor-immune interactions that dictate sensitivity to PD-1 blockade is essential for improving outcomes and optimizing immunotherapy personalization.
Methods
We performed compartment-specific (tumor/immune) spatial proteomic profiling (GeoMx) on a discovery cohort of 104 patients with advanced, PD-L1-high (tumor proportion score ≥50%) NSCLC treated with first-line pembrolizumab. Identified markers were further assessed using orthogonal methods in two independent early-stage NSCLC cohorts treated with neoadjuvant/perioperative chemo-immunotherapy: (a) NADIM trial (n=36) with bulk RNA-seq and (b) NeoITX_H12O cohort (N=41) with quantitative immunohistochemistry. Potential baseline prognostic value without immunotherapy was evaluated in the TCGA dataset (N=940). Functional validation was assessed using in vitro and in vivo (nude and syngeneic) models.
Results
We identified tumor-cell OX40L, but not immune-cell OX40L, as the single marker significantly associated with prolonged progression-free survival (PFS) and overall survival under single-agent pembrolizumab in patients with PD-L1-high tumors. Spatially resolved analysis linked tumor-intrinsic OX40L to an active immune microenvironment with increased antigen presentation. In both neoadjuvant/perioperative cohorts, high OX40L levels in residual tumors from patients with non-pathological complete response were associated with superior PFS. Conversely, no significant association with survival was observed in the immunotherapy-naïve TCGA cohort. Functional studies confirmed that OX40L-expressing NSCLC cells directly co-stimulate T cells in vitro and significantly enhance anti-PD-1 efficacy in vivo (p=0.0005), without affecting intrinsic tumor growth.
Conclusions
OX40L expressed by tumor cells contributes to an enhanced efficacy of PD-1 blockade in patients with NSCLC. These findings may open new therapeutic avenues and potentially contribute to improving immunotherapy personalization in this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tumor Microenvironment and Precision Oncology Research Group, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Community of Madrid, Spain.
- Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
- Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain.
- Department of Oncology, Hospital Universitario Fundación Alcorcón, Alcorcón, Spain.
Förderung
- Ministry of Science, Innovation, and Universities of Spain
- Fundacion Cris
- Asociación Española contra el Cáncer
- Comunidad Autónoma de Madrid
- CIBERONC
- Instituto de Salud Carlos III
- Fundación Fero
- Fundacion Mutua Madrileña
Zitieren
APA
Fernández-Luna, C., Baena, J., Calles, A., Antoñanzas-Basa, M., Lage Alfranca, Y., Mielgo, X., Sereno, M., Cervera, R., Cabezon-Gutierrez, L., López, A., Rubio, J., Conde, E., Lopez-Rios, F., Alvarez-Vallina, L., Valencia, K., Montuenga, L. M., Ruiz De Garibay, G., Molero, M., Adradas, V., …, & Zugazagoitia, J. (2026). Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-016133
Vancouver
Fernández-Luna C, Baena J, Calles A, Antoñanzas-Basa M, Lage Alfranca Y, Mielgo X, et al. Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2026-016133
BibTeX
@article{FernndezLuna2026,
author = {Fernández-Luna, Carmen and Baena, Javier and Calles, Antonio and Antoñanzas-Basa, Mónica and Lage Alfranca, Yolanda and Mielgo, Xabier and Sereno, Maria and Cervera, Raquel and Cabezon-Gutierrez, Luis and López, Ana and Rubio, Judit and Conde, Esther and Lopez-Rios, Fernando and Alvarez-Vallina, Luis and Valencia, Karmele and Montuenga, Luis M and Ruiz De Garibay, Gorka and Molero, Magdalena and Adradas, Vera and Curto-Aguilera, Daniel and Peressini, Melina and Carrera-Elvira, Esther and Ballesteros, Daniel and Portillo-Fernández, Adrián and Lopez-Cárdenas, Teresa and Serrano-Gómez, Cristina and Bote, Helena and Torres-Jiménez, Javier and Cruz-Bermúdez, Alberto and Provencio, Mariano and Paz-Ares, Luis and Sánchez-Herrero, Estela and Zugazagoitia, Jon},
title = {Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
doi = {10.1136/jitc-2026-016133}
}
EUVIMED